Reengineering of a commercially available bovine intravaginal insert (CIDR insert) containing progesterone

Rathbone, Michael J.

doi:10.1016/s0168-3659(02)00288-2

Cited by 71 publications

(75 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, incorporating the CIDR into the Ovsynch imposes an additional cost. Since insertion of the CIDR elevated the serum progesterone level to 1-2ng/ml up to 15 days (Uehlinger et al, 1995) and the 1.9 g and 1.38 g containing CIDR were found to have 1.3 and 0.7 g residual progesterone after 7 days using (Rathbone et al, 2002). It was suggested that CIDR used for a short period (5-7 days) can be reused to minimize the cost.…”

Section: Introductionmentioning

confidence: 99%

Efficiency of Previously used CIDR Stored for a Prolonged Period

Abdallah¹,

Elrahim²

2014

Adv. Anim. Vet. Sci.

View full text Add to dashboard Cite

| This study investigated the efficiency of the previously used controlled internal drug release (CIDR) stored for 30 days before reusing. In the first experiment, twenty seven Holstein cows at the day of estrus (day 0) received either no treatment (control), new or reused CIDR and blood samples were collected at day 0, 1, 3 and 7. At day 1 and 3, serum progesterone concentration in cows received new CIDR (1.417 and 1.616 ng/ml) was significantly higher than in cows received a reused one (0.545 and 0.954 ng/ml) which in turn was higher than the control group. In the second experiment, estrous cycle was synchronized using Ovsynch, New-CIDRsynch or Reused-CIDRsynch. Cows in Ovsynch (n=119) received GnRH on day 0 then PGF2α on day 7. Fifty six hours after the PGF2α cows received another dose from GnRH and inseminated 18 h latter. Cows in new-CIDRsynch (n=870) and reused-CIDRsynch (n=220) were treated in the same way with exception of inserting a new or reused CIDR between day 0 and day 7. Non returned cows were examined for pregnancy diagnosis at 30 and 70 days post-insemination. Pregnancy-30 and 70 rates after New-CIDRsynch (36.1% and 30.5%) and Reused-CIDRsynch (36.4% and 31.8%) tended to be higher than after Ovsynch (27.7% and 25.2%) (P= 0.07: 0.08). In conclusion, the previously used CIDR -stored for 30 days-have residual progesterone and incorporating new or reused CIDR into Ovsynch improved the efficiency of the protocol in a similar way.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficiency of Previously used CIDR Stored for a Prolonged Period

Abdallah¹,

Elrahim²

2014

Adv. Anim. Vet. Sci.

View full text Add to dashboard Cite

show abstract

“…Concentration was highest on the day of device insertion (4.1 ng/ml) and slowly declined to 1.9 ng/ml after 10 days of use. It is known from in vitro and in vivo drug release assessments that the CIDR insert releases on average approximately 89 mg of progesterone daily (Rathbone et al, 2001(Rathbone et al, , 2002) and the release is dependent primarily on the surface area of the device in contact with the mucosa of the vagina. However, it is unlikely that the delivery system is stable and not variable throughout the treatment period.…”

Section: Plasma Concentrations During Use Of Intravaginal Insertsmentioning

confidence: 99%

“…Cerri et al (2009) evaluated the concentrations of progesterone when estrous cyclic high-producing Holstein lactating cows received a new (1.38 g of progesterone) or a 7-day used CIDR insert after regressing the CL. The authors showed that a device releasing 89 mg of progesterone daily (Rathbone et al, 2001(Rathbone et al, , 2002 increased concentrations in plasma by approximately 0.8 to 1.0 ng/ml (Cerri et al, 2009). Concentrations increased in the first 15 min and reached a plateau by 90 min after insertion of the device.…”

Section: Plasma Concentrations During Use Of Intravaginal Insertsmentioning

confidence: 99%

“…Because release of progesterone from intravaginal devices is dependent primarily on the surface area in contact with the vaginal mucosa (Rathbone et al, 2001(Rathbone et al, , 2002, it is not a surprise that addition of multiple devices increases progesterone in plasma in a parallel manner to the number of inserts used (Macmillan et al, 1991;Lima et al, 2009). This is important because in many countries approval of new devices is costly, but opportunities exist for extra-label use of current devices to target individuals that might require daily doses of progesterone of at least 180 to 200 mg such as high-producing anovular dairy cows.…”

Section: Plasma Concentrations During Use Of Intravaginal Insertsmentioning

confidence: 99%

“…Such response likely explains the lack of benefit of a single intravaginal insert that results in 0.8 to 1.0 ng/ml in cows without a CL (Bisinotto and Santos, 2012). In fact, when progesterone was supplemented to cows without a CL with the use of 2 intravaginal inserts (Bisinotto et al, 2013(Bisinotto et al, , 2015a, to supply approximately 180 mg of progesterone released per day (Rathbone et al, 2001(Rathbone et al, , 2002, then the P/AI was similar to that of cows in diestrus when the timed AI protocol was initiated ( Table 2). The increments observed were of approximately 10 percentage units in P/AI (Bisinotto et al, 2013(Bisinotto et al, , 2015aLima et al, 2009).…”

Section: Supplemental Progesterone During the Timed Ai Protocol Accormentioning

confidence: 99%

See 2 more Smart Citations

Aspects and mechanisms of low fertility in anovulatory dairy cows

Santos¹,

Wiltbank²,

Ribeiro³

et al. 2016

Anim Reprod

View full text Add to dashboard Cite

Postpartum anovulation is a natural process that is observed in most mammals, including women. In lactating dairy cows, the interval from calving to first ovulation typically averages 4 to 5 weeks, but a substantial proportion of cows have not resumed estrous cyclicity by 60 days postpartum. Extended delay in resumption of first postpartum ovulation is known to exert long-lasting detrimental effects on fertility in dairy cows including the lack of spontaneous estrus and subsequent timely insemination postpartum, but when anovular cows have the estrous cycle synchronized for artificial insemination (AI), still pregnancy per AI is reduced and the risk of pregnancy loss increased. Many risk factors exist for extended postpartum anovulatory periods such as negative nutrient balance and diseases, and these risk factors are also known to depress fertility by themselves. A key feature in anovular cows when inseminated is that they develop the ovulatory follicle under subluteal or low concentrations of progesterone. Progesterone from the corpus luteum is pivotal for follicle development, oocyte competence, embryo growth, and endometrial function; however, many of these effects exerted by progesterone are mediated either by secretion of gonadotropins influencing follicular function and oocyte competence or by endometrial histotroph secretion influencing embryo/conceptus growth and developmental biology. Sub-optimal concentrations of progesterone during follicle growth in anovular cows affect morula and early blastocyst quality, alter conceptus gene expression and affect endometrial function increasing the synthesis of prostaglandin F2α . When anovular cows receive sufficient supplemental progesterone during the antral stages of development of the ovulatory follicle, then pregnancy per AI is reestablished and resembled that of estrous cyclic cows that developed the follicle during diestrus. Preliminary data suggest that a minimum concentration of progesterone during follicle growth is needed to optimize fertility in anovular cows, at least 2.0 ng/ml.

show abstract

Controlled Release Intravaginal Veterinary Drug Delivery

Rathbone

Burke

2012

Advances in Delivery Science and Technology

View full text Add to dashboard Cite

Reengineering of a commercially available bovine intravaginal insert (CIDR insert) containing progesterone

Cited by 71 publications

References 12 publications

Efficiency of Previously used CIDR Stored for a Prolonged Period

Efficiency of Previously used CIDR Stored for a Prolonged Period

Aspects and mechanisms of low fertility in anovulatory dairy cows

Controlled Release Intravaginal Veterinary Drug Delivery

Contact Info

Product

Resources

About